RemeGen Reports Positive Outcomes in Phase I/II Trial of Antibody-Drug Conjugate RC88
Monday, 3 June 2024, 22:48
RemeGen Reports Proof-of-Concept Phase I/II Clinical Study Results for RC88
RemeGen released the results from its Phase I/II clinical study on the antibody-drug conjugate RC88, indicating a significant milestone in cancer treatment.
Potential First-in-Class Advancement
RC88 has demonstrated promising efficacy and safety profiles, positioning it as a noteworthy candidate for future development in targeted cancer therapies.
- Study reveals significant outcomes
- RC88 shows potential as a groundbreaking treatment
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.